Home › Trials › NCT06744335

Observational study on chronic kidney disease diagnosis in patients with hypertension in Kazakhstan

Prospective Observational Multicenter Study of Patients With Arterial Hypertension and Chronic Kidney Disease Markers in Kazakhstan (PROGRESS-CKD)

Observational AstraZeneca · NCT06744335

This study looks at how often people with high blood pressure in Kazakhstan are diagnosed with chronic kidney disease and what signs they have that might indicate this condition.

Quick facts

Study typeObservational
Enrollment1282 (estimated)
Ages18 Years and up
SexAll
SponsorAstraZeneca Industry-sponsored
Locations29 sites (Temirlanovka, Turkistan Oblast and 28 other locations)
Trial IDNCT06744335 on ClinicalTrials.gov

What this trial studies

This multicenter, non-interventional observational study aims to evaluate the rate of chronic kidney disease (CKD) diagnosis among patients with arterial hypertension (AH) and specific CKD markers in Kazakhstan. The study will assess the proportion of patients exhibiting markers such as albuminuria/proteinuria and reduced glomerular filtration rate (GFR). It will also analyze demographic and clinical characteristics of these patients, along with their routine therapy before and after CKD diagnosis. The study will include both a full analysis of all patients and a modified analysis for those confirmed to have CKD during the study.

Who should consider this trial

Good fit: Ideal candidates for this study are adults aged 18 and older with a diagnosis of hypertension and laboratory markers indicating potential chronic kidney disease.

Not a fit: Patients without hypertension or those who have a documented diagnosis of chronic kidney disease prior to the study will not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance early diagnosis and management of chronic kidney disease in patients with hypertension, potentially improving patient outcomes.

How similar studies have performed: While there may be similar observational studies, this specific approach focusing on the intersection of hypertension and CKD markers in Kazakhstan is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

Age ≥18 years at the time of inclusion;

* Patient signed and dated written informed consent form (ICF) in accordance with ICH GCP and local legislation prior to inclusion in the study for the prospective observational cohort;
* Established diagnosis of hypertension, diagnosed in accordance with current clinical guidelines for hypertension, i.e. in adults, i.e. systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg. when measured at two different visits
* Laboratory markers of CKD (eGFR \<60 mL/min/1.73 m2 and/or albuminuria/proteinuria\*) measured during the period ≤12 months prior to inclusion in the study and persisting ≥3 months between two measurements without a recorded diagnosis of CKD in the primary medical record prior to inclusion;

  \* any of the following: urine albumin/creatinine ratio (UACR) ≥30 mg/g (3 mg/mmol), Urine protein-creatinine ratio (uPCR) ≥150 mg/g (15 mg/mmol), albuminuria ≥30 mg/d or Urine protein-creatinine ratio (uPCR) ≥0.15 mg/d.
* Absence of documented diagnosis of CKD in the patient's medical records prior to inclusion in the study

Exclusion Criteria:

* Absence of a signed ICF in patients in the prospective follow-up group

  * Participation in any randomized controlled trial within 3 months prior to inclusion in this study or during participation in this study
  * An established diagnosis of type 1 or type 2 diabetes mellitus.
  * Diagnosis of symptomatic chronic heart failure (CHF), NYHA functional class III-IV, documented in the patient's medical records
  * Diagnosis of AH of secondary genesis

Where this trial is running

Temirlanovka, Turkistan Oblast and 28 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Rate of CKD Diagnosis in Patients With AH and CKD MarkersDemographic and Clinical Characteristics for Those PatientsRoutine Therapy Before and After the Diagnosis of CKD
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.